Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty.
Al-Ani AyshaClarissa RentschRalley PrenticeDoug JohnsonRobert V BryantMark G WardSamuel Paul CostelloPeter LewindonSimon GhalySusan J ConnorJakob BegunBritt ChristensenPublished in: Internal medicine journal (2020)
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there is insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease patients in the context of the COVID-19 pandemic in the Australasian setting.
Keyphrases
- sars cov
- end stage renal disease
- public health
- healthcare
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- systematic review
- prognostic factors
- stem cells
- bone marrow
- staphylococcus aureus
- pseudomonas aeruginosa
- patient reported outcomes
- respiratory syndrome coronavirus
- social media
- medical education
- data analysis